Physician profile
Leslie Wright
NPI 1043077365
$1,170.93
in general payments reported to CMS, 2019-2025
18 companies · $675 in 2025
The $675 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $496 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.46 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $187.20 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $135.27 | 2024-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $87.66 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Viatris Specialty LLC | $65.56 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $50.00 | 2025 | Auvelity |
| Dexcom, INC. | $48.10 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $25.21 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $21.10 | 2025 | |
| Tris Pharma INC | $20.23 | 2024 | Dyanavel Xr |
| Antares Pharma, INC. | $19.71 | 2025 | Xyosted |
| Xeris Pharmaceuticals, INC. | $18.46 | 2025 | Gvoke Hypopen |
| Electromed, INC. | $16.37 | 2025 | Smartvest |
| Janssen Pharmaceuticals, INC | $16.30 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.24 | 2025 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $16.00 | 2024 | |
| Mylan Specialty L.P. | $14.98 | 2024 | Yupelri |
| Abbvie INC. | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.